Changing survival of people with myeloma and end stage kidney disease: A cohort study using Australian and New Zealand dialysis and transplant registry 1963 –2013
ConclusionsThe proportion of people with myeloma and ESKD remains stable, but their survival has progressively improved in Australia and New Zealand. On starting ESKD treatment with myeloma, a 59 year old without diabetes on peritoneal dialysis can expect a 45% 5 year survival, where a 75‐year‐old diabetic on haemodialysis has 9% 5 year survival.
Source: Nephrology - Category: Urology & Nephrology Authors: Angela C Webster, Ashley B Irish, Patrick J Kelly Tags: Original Article Source Type: research
More News: Australia Health | Diabetes | Dialysis | Endocrinology | Hemodialysis | Ireland Health | Kidney Transplant | Kidney Transplantation | Myeloma | New Zealand Health | Peritoneal Dialysis | Study | Transplant Surgery | Transplants | Urology & Nephrology